We’ve seen record numbers of Australian brain cancer patients enrolled in clinical trials and that number will only increase as Australians join the first in the world to take part in GBM AGILE.
Australians to be among
first to benefit from brain cancer research revolution
Cure Brain Cancer and Australian experts have been pivotal in developing GBM AGILE; the biggest global collaboration in the history of brain cancer, with more than 150 of the world’s brightest minds uniting to revolutionise the clinical trial process. Its aim is to develop more effective brain cancer treatments faster and at substantial cost savings, cutting red tape, delivering faster results. GBM AGILE is progressing well, getting us one step closer to seeing a world-first global adaptive trial. Thanks to your support, and Cure Brain Cancer Foundation’s involvement, Australians will be amongst the first in the world to benefit.
Kids with cancer to access
promising tailored treatments
Australian children are starting to benefit from one of the nation’s most exciting ever childhood cancer research initiatives - Zero Childhood Cancer. This year the first stage
opened to high risk NSW patients, and if successful, it will be widened to a
national clinical trial involving 120 children. Our consistent advocacy for
increased funding for childhood brain cancer helped secure an additional $20
million from the Federal Government for this promising clinical trial.
Australian patients enrol in world’s first brain cancer immunotherapy trial
Cure Brain Cancer Foundation is helping to fund a new immunotherapy treatment to target glioblastoma (GBM) without invasive surgery. This project has seen Australian researchers join forces with global counterparts to evaluate the effectiveness of the drug, Durvalumab, as part of a treatment that uses the body's own immune system to fight GBM.
We couldn’t have done it without you — thank you
As always, we're humbled by your support, encouragement, and belief in the Foundation. With every new research moment, we move closer towards meeting out mission of increasing five-year survival from 20 per cent to 50 per cent by 2023.
Cure Brain Cancer Foundation